Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders
Abstract Alterations in sodium flux (INa) play an important role in the pathogenesis of cardiac arrhythmias and may also contribute to the development of cardiomyopathies. We have recently demonstrated a critical role for the regulation of the voltage-gated sodium channel NaV1.5 in the heart by the...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9af9999edb46428491a8bdbba7942bc4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9af9999edb46428491a8bdbba7942bc4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9af9999edb46428491a8bdbba7942bc42021-12-02T16:08:13ZInhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders10.1038/s41598-017-00413-32045-2322https://doaj.org/article/9af9999edb46428491a8bdbba7942bc42017-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00413-3https://doaj.org/toc/2045-2322Abstract Alterations in sodium flux (INa) play an important role in the pathogenesis of cardiac arrhythmias and may also contribute to the development of cardiomyopathies. We have recently demonstrated a critical role for the regulation of the voltage-gated sodium channel NaV1.5 in the heart by the serum and glucocorticoid regulated kinase-1 (SGK1). Activation of SGK1 in the heart causes a marked increase in both the peak and late sodium currents leading to prolongation of the action potential duration and an increased propensity to arrhythmia. Here we show that SGK1 directly regulates NaV1.5 channel function, and genetic inhibition of SGK1 in a zebrafish model of inherited long QT syndrome rescues the long QT phenotype. Using computer-aided drug discovery coupled with in vitro kinase assays, we identified a novel class of SGK1 inhibitors. Our lead SGK1 inhibitor (5377051) selectively inhibits SGK1 in cultured cardiomyocytes, and inhibits phosphorylation of an SGK1-specific target as well as proliferation in the prostate cancer cell line, LNCaP. Finally, 5377051 can reverse SGK1’s effects on NaV1.5 and shorten the action potential duration in induced pluripotent stem cell (iPSC)-derived cardiomyocytes from a patient with a gain-of-function mutation in Nav 1.5 (Long QT3 syndrome). Our data suggests that SGK1 inhibitors warrant further investigation in the treatment of cardiac arrhythmias.Vassilios J. BezzeridesAifeng ZhangLing XiaoBridget SimonsonSantosh A. KhedkarShiro BabaFilomena OttavianoStacey LynchKatherine HesslerAlan C. RigbyDavid MilanSaumya DasAnthony RosenzweigNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Vassilios J. Bezzerides Aifeng Zhang Ling Xiao Bridget Simonson Santosh A. Khedkar Shiro Baba Filomena Ottaviano Stacey Lynch Katherine Hessler Alan C. Rigby David Milan Saumya Das Anthony Rosenzweig Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| description |
Abstract Alterations in sodium flux (INa) play an important role in the pathogenesis of cardiac arrhythmias and may also contribute to the development of cardiomyopathies. We have recently demonstrated a critical role for the regulation of the voltage-gated sodium channel NaV1.5 in the heart by the serum and glucocorticoid regulated kinase-1 (SGK1). Activation of SGK1 in the heart causes a marked increase in both the peak and late sodium currents leading to prolongation of the action potential duration and an increased propensity to arrhythmia. Here we show that SGK1 directly regulates NaV1.5 channel function, and genetic inhibition of SGK1 in a zebrafish model of inherited long QT syndrome rescues the long QT phenotype. Using computer-aided drug discovery coupled with in vitro kinase assays, we identified a novel class of SGK1 inhibitors. Our lead SGK1 inhibitor (5377051) selectively inhibits SGK1 in cultured cardiomyocytes, and inhibits phosphorylation of an SGK1-specific target as well as proliferation in the prostate cancer cell line, LNCaP. Finally, 5377051 can reverse SGK1’s effects on NaV1.5 and shorten the action potential duration in induced pluripotent stem cell (iPSC)-derived cardiomyocytes from a patient with a gain-of-function mutation in Nav 1.5 (Long QT3 syndrome). Our data suggests that SGK1 inhibitors warrant further investigation in the treatment of cardiac arrhythmias. |
| format |
article |
| author |
Vassilios J. Bezzerides Aifeng Zhang Ling Xiao Bridget Simonson Santosh A. Khedkar Shiro Baba Filomena Ottaviano Stacey Lynch Katherine Hessler Alan C. Rigby David Milan Saumya Das Anthony Rosenzweig |
| author_facet |
Vassilios J. Bezzerides Aifeng Zhang Ling Xiao Bridget Simonson Santosh A. Khedkar Shiro Baba Filomena Ottaviano Stacey Lynch Katherine Hessler Alan C. Rigby David Milan Saumya Das Anthony Rosenzweig |
| author_sort |
Vassilios J. Bezzerides |
| title |
Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| title_short |
Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| title_full |
Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| title_fullStr |
Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| title_full_unstemmed |
Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| title_sort |
inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/9af9999edb46428491a8bdbba7942bc4 |
| work_keys_str_mv |
AT vassiliosjbezzerides inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT aifengzhang inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT lingxiao inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT bridgetsimonson inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT santoshakhedkar inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT shirobaba inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT filomenaottaviano inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT staceylynch inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT katherinehessler inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT alancrigby inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT davidmilan inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT saumyadas inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders AT anthonyrosenzweig inhibitionofserumandglucocorticoidregulatedkinase1asnoveltherapyforcardiacarrhythmiadisorders |
| _version_ |
1718384546296102912 |